How genetic modifiers influence the phenotype of spinal muscular atrophy and suggest future therapeutic approaches

被引:76
|
作者
Wirth, Brunhilde [1 ]
Garbes, Lutz [1 ]
Riessland, Markus [1 ]
机构
[1] Univ Cologne, Inst Genet, Inst Human Genet, Ctr Mol Med Cologne, Cologne, Germany
关键词
SURVIVAL-MOTOR-NEURON; SMA MOUSE MODEL; VALPROIC ACID INCREASES; SMN2 COPY NUMBER; DIGENIC INHERITANCE; MENDELIAN DISORDERS; EMBRYONIC LETHALITY; DISEASE SEVERITY; CIRCUIT FUNCTION; PROTEIN-LEVELS;
D O I
10.1016/j.gde.2013.03.003
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Both complex disorders and monogenetic diseases are often modulated in their phenotype by further genetic, epigenetic or extrinsic factors. This gives rise to extensive phenotypic variability and potentially protection from disease manifestations, known as incomplete penetrance. Approaches including whole transcriptome, exome, genome, methylome or proteome analyses of highly discordant phenotypes in a few individuals harboring mutations at the same locus can help to identify these modifiers. This review describes the complexity of modifying factors of one of the most frequent autosomal recessively inherited disorders in humans, spinal muscular atrophy (SMA). We will outline how this knowledge contributes to understanding of the regulatory networks and molecular pathology of SMA and how this knowledge will influence future approaches to therapies.
引用
收藏
页码:330 / 338
页数:9
相关论文
共 50 条
  • [31] Spinal muscular atrophy: An update on therapeutic progress
    Seo, Joonbae
    Howell, Matthew D.
    Singh, Natalia N.
    Singh, Ravindra N.
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2013, 1832 (12): : 2180 - 2190
  • [32] Spinal muscular atrophy - challenges in the therapeutic era
    Faravelli, Irene
    Corti, Stefania
    NATURE REVIEWS NEUROLOGY, 2020, 16 (12) : 655 - 656
  • [33] Novel therapeutic strategies for spinal muscular atrophy
    Khwaja, Omar
    Clarke, Ellen
    FUTURE NEUROLOGY, 2015, 10 (04) : 309 - 311
  • [34] Spinal muscular atrophy: mechanisms and therapeutic strategies
    Lorson, Christian L.
    Rindt, Hansjorg
    Shababi, Monir
    HUMAN MOLECULAR GENETICS, 2010, 19 : R111 - R118
  • [35] Spinal Muscular Atrophy (SMA) in the Therapeutic Era
    Gibbons, Melissa
    Stratton, Anne
    Parsons, Julie
    CURRENT GENETIC MEDICINE REPORTS, 2019, 7 (03) : 162 - 167
  • [36] Spinal Muscular Atrophy and Common Therapeutic Advances
    Qomi, Saeed Bozorg
    Asghari, Amir
    Salmaninejad, Arash
    Mojarrad, Majid
    FETAL AND PEDIATRIC PATHOLOGY, 2019, 38 (03) : 226 - 238
  • [37] DcpS as a Therapeutic Target for Spinal Muscular Atrophy
    Singh, Jasbir
    Salcius, Michael
    Liu, Shin-Wu
    Staker, Bart L.
    Mishra, Rama
    Thurmond, John
    Michaud, Gregory
    Mattoon, Dawn R.
    Printen, John
    Christensen, Jeffery
    Bjornsson, Jon Mar
    Pollok, Brian A.
    Kiledjian, Megerditch
    Stewart, Lance
    Jarecki, Jill
    Gurney, Mark E.
    ACS CHEMICAL BIOLOGY, 2008, 3 (11) : 711 - 722
  • [38] Recent therapeutic developments in spinal muscular atrophy
    Bora, Gamze
    Yesbek Kaymaz, Ayse
    Bekircan Kurt, Can Ebru
    Haliloglu, Vildan Goknur
    Topaloglu, Haluk Aydin
    Erdem Yurter, Hayat
    Erdem Ozdamar, Sevim
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2018, 48 (02) : 203 - 211
  • [39] Spinal muscular atrophy — challenges in the therapeutic era
    Irene Faravelli
    Stefania Corti
    Nature Reviews Neurology, 2020, 16 : 655 - 656
  • [40] Therapeutic strategies for the treatment of spinal muscular atrophy
    Cherry, Jonathan J.
    Androphy, Elliot J.
    FUTURE MEDICINAL CHEMISTRY, 2012, 4 (13) : 1733 - 1750